Kymriah® (tisagenlecleucel, formerly CTL019) receives European Commission Approval
London, UK – 28 August 2018: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today notes that the European Commission (EC) has…